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Abstract: Myocardial perfusion studies use either physical exercise or pharmacologic vasodila-
tor stress to induce maximum myocardial hyperemia. Adenosine and dipyridamole are the most 
commonly used agents to induce coronary arterial vasodilation for myocardial perfusion imag-
ing. Both cause frequent undesirable side-effects. Because of its ultrashort half-life, adenosine 
must be administered by constant intravenous infusion during the examination. A key feature 
of an ideal A2A agonist for myocardial perfusion imaging studies would be an optimal level 
and duration of hyperemic response. Drugs with a longer half-time and more selective A2A 
adenosine receptor agonism, such as regadenoson, should theoretically result in a similar degree 
of coronary vasodilation with fewer or less severe side-effects than non-selective, ultrashort-
lasting adenosine receptor stimulation. The available preclinical and clinical data suggest that 
regadenoson is a highly subtype-selective, potent, low-afﬁ  nity A2A adenosine receptor agonist 
that holds promise for future use as a coronary vasodilator in myocardial perfusion imaging 
studies. Infusion of regadenoson achieves maximum coronary hyperemia that is equivalent to 
adenosine. After a single bolus infusion over 10 s, hyperemia is maintained signiﬁ  cantly longer 
(approximately 2–5 min) than with adenosine, which should facilitate radionuclide distribution 
for myocardial perfusion imaging studies. In comparison with the clinically competitive A2A 
adenosine receptor agonist binodenoson, regadenoson has a several-fold shorter duration of 
action, although the magnitude of hyperemic response is comparable between the two. The more 
rapid termination of action of regadenoson points to an advantage of enhanced control for the 
clinical application. Regadenoson selectively causes vasodilation of the coronary circulation, 
whereas effects on systemic blood pressure are only mild. The clinical adverse effect proﬁ  le 
of regadenoson appears to be favorable, particularly with respect to dreaded atrioventricular 
conduction disturbances and bronchospasm.
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Introduction
Non-invasive imaging of relative regional myocardial perfusion by stress single photon 
emission computerized tomography (SPECT), magnetic resonance imaging (MRI), 
positron emission tomography (PET), or contrast-enhanced echocardiography plays 
an important role in the diagnosis of coronary artery disease (CAD) (Baghdasarian 
and Heller 2005). Myocardial perfusion studies use either physical exercise or phar-
macologic vasodilator stress to induce maximum myocardial hyperemia. Adenosine 
and dipyridamole are the most commonly used agents to induce coronary arterial 
vasodilation for myocardial perfusion imaging. Both are given as a continuous infu-
sion and act by a ﬁ  nal common pathway: stimulating adenosine A2A receptors on 
arteriolar vascular smooth muscle cells. Unfortunately this effect is non-selective 
and there is activation of adenosine A1, A2B, and A3 receptors, which results in 
frequent undesirable side-effects such as chest pain and dyspnea, and less frequent 
but serious side-effects such as bronchospasm and high-grade atrioventricular (AV) Vascular Health and Risk Management 2008:4(2) 338
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block (Ranhosky and Kempthorne-Rawson 1990; Cerqueira 
et al 1994). In addition, hypotension resulting from adenos-
ine-induced vasodilation in the peripheral circulation is 
another undesirable effect that limits the clinical usefulness 
of adenosine (Cerqueira 2004).
Because of its ultrashort half-life, adenosine must be 
administered by constant intravenous infusion during the 
examination. Bolus administration would obviate the need 
for an infusion pump, simplifying drug delivery during the 
examination. Another key feature of an ideal A2A agonist 
for myocardial perfusion imaging studies would be an 
optimal level and duration of hyperemic response. A rapid 
2- to 3-fold increase in coronary blood ﬂ  ow is required. 
In addition, hyperemia should be maintained to allow for 
adequate distribution of radionuclides within the myocardium 
(Cerqueira 2004). The time course of hyperemia should be as 
short as possible to minimize the risk of side-effects. On the 
other hand, hyperemia should be long enough (approximately 
2–4 min) to allow maximal extraction of the radiotracer dur-
ing the induced heterogeneous blood ﬂ  ow for detection of 
disparities caused by obstructive CAD (Cerqueira 2004).
Therefore, drugs with a longer half-life and more selec-
tive A2A adenosine receptor agonism should theoretically 
result in a similar degree of coronary vasodilation with fewer 
or less severe side-effects than non-selective, ultrashort-
lasting adenosine receptor stimulation. There is however a 
large A2A receptor “reserve” in the coronary artery, so that 
an ideal A2A agonist may well have a low afﬁ  nity (Belar-
dinelli et al 1996). Since the discovery of the prototypical 
A2A agonist CGS-21680 in 1989, several potent, selective 
A2A adenosine receptor agonists have been synthesized, 
and preliminary experimental studies have been promising. 
Currently, three selective adenosine A2A receptor agonists 
have begun phase III studies as pharmacologic stress agents, 
regadenoson (CVT3146; CV Therapeutics, Inc. and Astellas 
Pharma, Inc.), binodenoson (MRE0470 or WRC0470; King 
Pharmaceuticals R&D Inc), and apadenoson (BMS068645 
or ATL146e). This article reviews the preclinical and clini-
cal studies of regadenoson with respect to its potential for 
myocardial perfusion imaging.
Synthesis and structure activity 
relationship (SAR)
Regadenoson is a 2-[N-1-(4-N-methylcarboxamidopyra-
zolyl)]-adenosine derivative. There are three biochemical 
classes of A2A adenosine receptor agonists based on two 
different 2-substituted adenosine derivatives. The first 
of these classes contains a pi system at the 2-position; 
for example, the acetylenic and trans double bonds 
of YT-146 (2-(1-octynyl)adenosine) and THENECA 
(2-(trans-1-hexenyl)adenosine), respectively, are used 
to extend a hydrophobic chain into a putative lipophilic 
pocket in the A2A receptor. A second class of A2A ago-
nists contains a 2-heteroatom alkyl linker to a hydrophobic 
group (eg, CGS-21680). A third class of 2-substituted A2A 
adenosine agonists contains both a 2-heteroatom linker and 
a pi system (eg, binodenoson). Binodenoson has been dem-
onstrated to be functionally selective for the A2A adenosine 
receptor, relative to the A1 receptor. Regadenoson has a 
152° trajectory, similarly to THENECA, but contains a 
2-heteroatom linker and a pi system like that of binodenoson 
(Zablocki et al 2001). Previous research had demonstrated 
that 2-(3,5-disubstituted-N-pyrazolyl)-adenosine deriva-
tives were inactive at doses of up to 100 µg as coronary 
vasodilators, and further SAR investigation suggested that 
an extended presentation of the 4-substituted pyrazole would 
be preferred for selective binding at the A2A receptor (Palle 
et al 2000). During biochemical binding studies, regadeno-
son was found to be a short-acting coronary vasodilator 
(t1/2 = 5.2 ± 0.2 min) with good potency (EC50 = 6.4 ± 1.2 nM) 
and functional selectivity for the A2A adenosine receptor 
versus the A1 receptor (Zablocki et al 2000).
Regadenoson was prepared as part of a series of 2-(N or 
C-pyrazolyl) adenosine derivatives including CVT-2995, 
CVT-3033, CVT-3032 and regadenoson, which, when char-
acterized by radioligand binding and cAMP assays, exhibited 
Ki values at A2A and A1 adenosine receptors of 305 and 866, 
2895 and 5836, 13651 and 6350, and 1269 and 16460 nM, 
respectively. The decline in cAMP accumulation elicted in 
PC-12 cells was inversely related (R2 = 0.85) to the afﬁ  nity 
of the agonist for the receptor (Gao et al 2000).
Regadenoson was synthesized from 2-hydrazino-
adenosine in two steps. Ethoxycarbonylmalondialdehyde 
was condensed with 2-hydrazinoadenosine in a 1:1 mixture 
of ethanoic acid and methanol. The resulting 2-ester was then 
converted directly to the amide regadenoson by aminolysis 
with methylamine (Palle et al 2002). Regadenoson could also 
be synthesized from 2-chloro or 2-iodo adenosine derivatives 
(Palle et al 2000; Zablocki et al 2000).
Clinical development
Kerensky et al (2002) examined the effects of regadenoson 
on cerebral blood ﬂ  ow (CBF) velocity as assessed by Doppler 
ﬂ  ow wire in 36 patients undergoing clinically indicated 
coronary catheterization. Regadenoson (10–500 µg) caused 
a rapid increase in CBF velocity that was near peak within Vascular Health and Risk Management 2008:4(2) 339
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30–40 s after peripheral intravenous bolus injection. The 
maximum peak to baseline CBF velocity ratio was 3.2 ± 0.6, 
and was similar to that obtained by intracoronary injection 
of adenosine (3.2 ± 0.5). The duration of CBF velocity aug-
mentation (at least 2-fold increase) was dose dependent; at 
300 µg the duration was 4.0 ± 4.9 min and at 500 µg was 
6.9 ± 7.6 min. At the maximal applied dose of 500 µg, the 
increase in heart rate was 18.7 ± 4.0 bpm and the maximal 
decrease in systolic blood pressure was 8.7 ± 7.6 mmHg.
Hendel et al (2003) compared regadenoson and adenosine 
for myocardial perfusion imaging using stress-SPECT in 35 
patients. Regadenoson was administered by a intravenous 
bolus injection of 400 or 500 µg. There were no differences 
in ischemia detection between regadenoson-SPECT and 
adenosine-SPECT, with a regional concordance for ischemia 
extent and severity of 86.3% and 83.4%, respectively.
ADVANCE MPI 1 is a pivotal phase III, multi-national, 
randomized, double-blind trial that was initiated in October 
2003 [www.clinicaltrials.gov]. In this multinational trial, 
involving 784 patients with coronary artery disease undergo-
ing SPECT, patients were randomized to either adenosine 
SPECT or regadenoson SPECT. The trial was designed to 
compare the pharmacological stress SPECT images used 
to assess reversible perfusion defects and to compare the 
safety and tolerability of the two stress agents. In late 2005 
it was reported that the primary endpoint of the study was 
met, suggesting that regadenoson SPECT was comparable 
with adenosine SPECT at detecting areas of the heart with 
reduced blood ﬂ  ow (CV Therapeutics, Inc. 2005a, b). The 
most common adverse events were headache, chest pain, 
shortness of breath, ﬂ  ushing and gastrointestinal discomfort 
(CV Therapeutics, Inc. 2005a). This preliminary information 
has to be interpreted with caution until the ﬁ  nal results are 
published in scientiﬁ  c format.
Side-effects and contraindications
Hendel et al (2004) reported safety and tolerability of 
regadenoson for 36 patients. Although adverse events were 
reported rather frequently (in 72% of patients), these were 
mostly of minor clinical importance (96%) and resolved 
within 15 minutes without treatment in 91% of cases. Chest 
discomfort, headache, and abdominal pain were the most 
common side-effects and were similar distributed between 
regadenoson low and high dose groups. Flushing, dyspnea, 
and dizziness were, however, more frequently encountered 
in the higher dose group. So far, AV conduction abnormali-
ties or relevant bronchoconstriction have not been reported. 
Hemodynamic effects of regadenoson included a decrease 
in blood pressure (–5.9 ± 10.7 mmHg) and increase of heart 
rate (+21.9 ± 10.4 bpm) (Hendel et al 2004).
Current opinion
So far, the available preclinical and clinical data suggest 
that regadenoson is a highly subtype-selective, potent, low-
afﬁ  nity A2A adenosine receptor agonist that holds promise 
for future use as a coronary vasodilator in myocardial 
Figure 1 Time course of changes in coronary conductance caused by regadenoson, binodenoson, CGS21680, and adenosine. Reprinted with permission from Gao Z, Otero 
DH, Zablocki JA, et al 2000. Pharmacological characterization of novel A2A adenosine receptor (A2AAdoR) agonists. Drug Dev Res, 50:93. Copyright© Wiley-Liss, Inc., a sub-
sidiary of John Wiley & Sons, Inc.Vascular Health and Risk Management 2008:4(2) 340
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perfusion imaging studies. Peripheral intravenous infusion 
of a regadenoson achieves maximum coronary hyperemia 
equivalent to that achieved with adenosine. After a single 
bolus infusion over 10s, hyperemia is maintained signiﬁ  -
cantly longer (approximately 2–5 min) than with adenos-
ine, which should facilitate radionuclide distribution for 
myocardial perfusion imaging studies. In comparison with 
the clinically competitive A2A adenosine receptor agonist 
binodenoson, regadenoson has a several-fold shorter duration 
of action, although the magnitude of hyperemic response is 
comparable between the two.
The more rapid termination of action of regadenoson 
points to an advantage of enhanced control for the clinical 
application. As a low-afﬁ  nity A2A receptor agonist, regad-
enoson selectively causes vasodilation of the coronary 
circulation, whereas effects on systemic blood pressure are 
only mild. According to its functional selectivity on the A2A 
adenosine receptor, AV conduction abnormalities or bron-
choconstriction were not observed in preclinical studies.
Preliminary clinical data suggest that a bolus of 400 µg 
administered by peripheral intravenous injection is sufﬁ  cient 
to achieve maximum coronary hyperemia that lasts for 
approximately 4–7 min. The clinical adverse effect proﬁ  le 
of regadenoson appears to be favorable, particularly with 
respect to the dreaded AV conduction disturbances and 
bronchospasm; however, the current side-effect proﬁ  le of 
regadenoson is based on only small populations of patients. 
Therefore, larger-scale studies are mandatory to reliably 
establish the clinical safety of regadenoson and its usefulness 
for myocardial perfusion imaging studies.
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